AU2012244549B2 - Heterocyclic compounds as kinase inhibitors - Google Patents

Heterocyclic compounds as kinase inhibitors Download PDF

Info

Publication number
AU2012244549B2
AU2012244549B2 AU2012244549A AU2012244549A AU2012244549B2 AU 2012244549 B2 AU2012244549 B2 AU 2012244549B2 AU 2012244549 A AU2012244549 A AU 2012244549A AU 2012244549 A AU2012244549 A AU 2012244549A AU 2012244549 B2 AU2012244549 B2 AU 2012244549B2
Authority
AU
Australia
Prior art keywords
pyrazolo
quinolin
methoxy
amine
amino
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2012244549A
Other languages
English (en)
Other versions
AU2012244549A1 (en
Inventor
Michael Almstetter
Roland Koestler
Michael Thormann
Andreas Treml
Nasser YEHIA
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Origenis GmbH
Original Assignee
Origenis GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Origenis GmbH filed Critical Origenis GmbH
Publication of AU2012244549A1 publication Critical patent/AU2012244549A1/en
Application granted granted Critical
Publication of AU2012244549B2 publication Critical patent/AU2012244549B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/08—Antiseborrheics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D495/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains three hetero rings
    • C07D513/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Biomedical Technology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Transplantation (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Otolaryngology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
AU2012244549A 2011-04-21 2012-04-23 Heterocyclic compounds as kinase inhibitors Active AU2012244549B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161517581P 2011-04-21 2011-04-21
US61/517,581 2011-04-21
PCT/EP2012/001736 WO2012143143A1 (en) 2011-04-21 2012-04-23 Heterocyclic compounds as kinase inhibitors

Publications (2)

Publication Number Publication Date
AU2012244549A1 AU2012244549A1 (en) 2013-10-31
AU2012244549B2 true AU2012244549B2 (en) 2017-04-20

Family

ID=46001141

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2012244549A Active AU2012244549B2 (en) 2011-04-21 2012-04-23 Heterocyclic compounds as kinase inhibitors

Country Status (25)

Country Link
US (1) US9499535B2 (enExample)
EP (1) EP2699572B1 (enExample)
JP (1) JP6278406B2 (enExample)
KR (1) KR101649610B1 (enExample)
CN (1) CN103717597B (enExample)
AP (1) AP2013007252A0 (enExample)
AU (1) AU2012244549B2 (enExample)
BR (1) BR112013026744B1 (enExample)
CA (1) CA2831680C (enExample)
CL (1) CL2013003052A1 (enExample)
CO (1) CO6831983A2 (enExample)
CR (1) CR20130537A (enExample)
CU (1) CU20130144A7 (enExample)
EA (1) EA034193B1 (enExample)
EC (1) ECSP13012984A (enExample)
GT (1) GT201300259A (enExample)
IL (1) IL228967B (enExample)
MA (1) MA35123B1 (enExample)
MX (1) MX365784B (enExample)
PE (1) PE20140927A1 (enExample)
PH (1) PH12013502184A1 (enExample)
SG (1) SG194216A1 (enExample)
TN (1) TN2013000422A1 (enExample)
TW (1) TWI557121B (enExample)
WO (1) WO2012143143A1 (enExample)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012143143A1 (en) 2011-04-21 2012-10-26 Origenis Gmbh Heterocyclic compounds as kinase inhibitors
ES2615734T3 (es) 2011-04-21 2017-06-08 Gilead Sciences, Inc. Compuestos de benzotiazol y su uso farmacéutico
US9376392B2 (en) 2012-01-04 2016-06-28 Gilead Sciences, Inc. 2-(tert-butoxy)-2-(7-methylquinolin-6-yl) acetic acid derivatives for treating AIDS
US9284323B2 (en) 2012-01-04 2016-03-15 Gilead Sciences, Inc. Naphthalene acetic acid derivatives against HIV infection
AR090650A1 (es) 2012-04-12 2014-11-26 Alcon Res Ltd Tratamiento para respuestas inflamatorias inducidas por microbios en el ojo
KR20150027267A (ko) 2012-06-29 2015-03-11 화이자 인코포레이티드 LRRK2 억제제로서의 4-(치환된-아미노)-7H-피롤로[2,3-d]피리미딘
CN112587658A (zh) 2012-07-18 2021-04-02 博笛生物科技有限公司 癌症的靶向免疫治疗
US10000482B2 (en) 2012-10-19 2018-06-19 Origenis Gmbh Kinase inhibitors
PL2970333T3 (pl) * 2013-03-15 2017-12-29 Oncodesign S.A. Makrocykliczne inhibitory kinazy LRRK2
EP3035800B1 (en) 2013-08-22 2019-10-09 Merck Sharp & Dohme Corp. Compounds inhibiting leucine-rich repeat kinase enzyme activity
JP6992960B2 (ja) * 2013-12-02 2022-02-03 ベルゲンビオ アーエスアー キナーゼ阻害剤の用途
US9695171B2 (en) 2013-12-17 2017-07-04 Pfizer Inc. 3,4-disubstituted-1 H-pyrrolo[2,3-b]pyridines and 4,5-disubstituted-7H-pyrrolo[2,3-c]pyridazines as LRRK2 inhibitors
US10548985B2 (en) 2014-01-10 2020-02-04 Birdie Biopharmaceuticals, Inc. Compounds and compositions for treating EGFR expressing tumors
CA2954446A1 (en) 2014-07-09 2016-01-14 Shanghai Birdie Biotech, Inc. Anti-pd-l1 combinations for treating tumors
EP3166637B1 (en) 2014-07-10 2020-01-29 The J. David Gladstone Institutes Compositions and methods for treating dengue virus infection
CN112546238A (zh) 2014-09-01 2021-03-26 博笛生物科技有限公司 用于治疗肿瘤的抗-pd-l1结合物
US11135206B2 (en) * 2015-05-26 2021-10-05 Kaohsiung Medical University Pyrazolo[4,3-c]quinoline derivatives for inhibition of β-glucuronidase
JP6873980B2 (ja) * 2015-09-14 2021-05-19 ファイザー・インク ＬＲＲＫ２阻害薬としての新規のイミダゾ［４，５−ｃ］キノリンおよびイミダゾ［４，５−ｃ］［１，５］ナフチリジン誘導体
CN105664178B (zh) * 2015-09-24 2019-08-20 洪健 Syk作为肝纤维化/硬化治疗靶点的应用
CN106943596A (zh) 2016-01-07 2017-07-14 博笛生物科技（北京）有限公司 用于治疗肿瘤的抗-cd20组合
CN115350279A (zh) 2016-01-07 2022-11-18 博笛生物科技有限公司 用于治疗肿瘤的抗-her2组合
CN115252792A (zh) 2016-01-07 2022-11-01 博笛生物科技有限公司 用于治疗肿瘤的抗-egfr组合
US10034861B2 (en) 2016-07-04 2018-07-31 H. Lundbeck A/S 1H-pyrazolo[4,3-b]pyridines as PDE1 inhibitors
NZ755222A (en) 2016-12-20 2022-07-01 Astrazeneca Ab Amino-triazolopyridine compounds and their use in treating cancer
CN110678178B (zh) * 2017-03-16 2023-10-03 百时美施贵宝公司 Mk2抑制剂的形式和组合物
CN108794467A (zh) * 2017-04-27 2018-11-13 博笛生物科技有限公司 2-氨基-喹啉衍生物
CA3067268A1 (en) 2017-06-23 2018-12-27 Birdie Biopharmaceuticals, Inc. Crystalline resiquimod monosulfate anhydrate and its preparation and uses
AR113926A1 (es) 2017-12-14 2020-07-01 H Lundbeck As Derivados de 1h-pirazolo[4,3-b]piridinas
MX2020006174A (es) 2017-12-14 2022-09-27 H Lundbeck As Tratamientos de combinación que comprenden la administración de 1h-pirazol[4,3-b]piridinas.
CN111511742B (zh) 2017-12-20 2023-10-27 H.隆德贝克有限公司 作为PDE1抑制剂的吡唑并[4,3-b]吡啶和咪唑并[1,5-a]嘧啶
BR112020021539A2 (pt) * 2018-04-25 2021-01-19 Innate Tumor Immunity, Inc. Moduladores de nlrp3
JP2020132986A (ja) * 2019-02-25 2020-08-31 東京エレクトロン株式会社 成膜用組成物および成膜方法
CN116854706B (zh) * 2019-04-18 2025-11-04 四川科伦博泰生物医药股份有限公司 稠环化合物、其制备方法及用途
PT4028017T (pt) * 2019-09-13 2024-01-16 Origenis Gmbh Derivados de 1,4-di-hidrobenzo[d]pirazolo[3,4-f][1,3]diazepina e compostos relacionados como moduladores das cinases lrrk2, nuak1 e/ou tyk2 para o tratamento de, por exemplo, doenças autoimunes
CA3154131A1 (en) 2019-09-13 2021-03-18 Origenis Gmbh 1,4-dihydrobenzo[d]pyrazolo[3,4-f][1,3]diazepine derivatives and related compounds as lrrk2, nuak1 and/or tyk2 kinase modulators for the treatment of e.g. autoimmune disease
EP4061374A1 (en) * 2019-11-20 2022-09-28 Yale University Compounds, compositions, and methods for treating ischemia-reperfusion injury and/or lung injury
WO2021207141A1 (en) * 2020-04-06 2021-10-14 The Regents Of The University Of Colorado, A Body Corporate METHODS OF USING NEUROKININ-1 RECEPTOR (NK-1R) ANTAGONISTS TO TREAT β-CORONAVIRUS INFECTION INCLUDING SARS-COV-2 INFECTION AND/OR COVID-19 DISEASE
JP7752675B2 (ja) * 2020-07-06 2025-10-10 アカデミー オブ ミリタリー メディカル サイエンシズ ウイルスに対するタウロリジンの使用
WO2022079250A1 (en) * 2020-10-16 2022-04-21 Merck Patent Gmbh Compounds for the treatment of viral infections
CN112138015B (zh) * 2020-10-22 2022-08-05 合肥博思科创医药科技有限公司 三苄糖苷在治疗微循环障碍引起的皮肤疾病中的应用
CN116940353A (zh) * 2020-10-26 2023-10-24 神经元23公司 与野生型lrrk2相关的帕金森氏病的治疗和诊断方法
EP4286386A4 (en) * 2021-02-03 2025-03-12 Ocumension Therapeutics (Suzhou) Co., Ltd. Salt form and crystal form of a pyrazole-substituted imidazo[1,2-a]quinoxaline derivative
WO2023076404A1 (en) 2021-10-27 2023-05-04 Aria Pharmaceuticals, Inc. Methods for treating systemic lupus erythematosus
CN116808016A (zh) * 2022-01-13 2023-09-29 浙江中医药大学 依普黄酮在抑制炎症小体活化中的应用
US11981676B1 (en) 2024-01-16 2024-05-14 King Faisal University Pyrazolo[4,3-c][2,6]naphthyridines as CK2 inhibitors

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009155527A2 (en) * 2008-06-19 2009-12-23 Progenics Pharmaceuticals, Inc. Phosphatidylinositol 3 kinase inhibitors
WO2010030785A2 (en) * 2008-09-10 2010-03-18 Kalypsys Inc. Heterocyclic inhibitors of histamine receptors for the treatment of disease

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CY1357A (en) 1979-06-21 1987-08-07 Ciba Geigy Ag Pyrazolo-quinolines, processes for their production, pharmaceutical compositions containing them and their therapeutical use
US5360720A (en) 1993-10-08 1994-11-01 Alcon Laboratories, Inc. Method of preparing human conjunctival mast cells for mast cell stabilization assays
US5723608A (en) 1996-12-31 1998-03-03 Neurogen Corporation 3-aryl substituted pyrazolo 4,3-d!pyrimidine derivatives; corticotropin-releasing factor receptor (CRF1) specific ligands
US6531475B1 (en) 1998-11-12 2003-03-11 Neurocrine Biosciences, Inc. CRF receptor antagonists and methods relating thereto
GB0106661D0 (en) 2001-03-16 2001-05-09 Pfizer Ltd Pharmaceutically active compounds
CA2540598C (en) * 2003-10-03 2013-09-24 3M Innovative Properties Company Pyrazolopyridines and analogs thereof
US7544697B2 (en) * 2003-10-03 2009-06-09 Coley Pharmaceutical Group, Inc. Pyrazolopyridines and analogs thereof
US7384930B2 (en) * 2004-11-03 2008-06-10 Bristol-Myers Squibb Company Constrained compounds as CGRP-receptor antagonists
EP1863814A1 (en) * 2005-04-01 2007-12-12 Coley Pharmaceutical Group, Inc. 1-substituted pyrazolo (3,4-c) ring compounds as modulators of cytokine biosynthesis for the treatment of viral infections and neoplastic diseases
JP2008538119A (ja) * 2005-04-01 2008-10-09 コーリー ファーマシューティカル グループ，インコーポレーテッド ピラゾロ［３，４−ｃ］キノリン類、ピラゾロ［３，４−ｃ］ナフチリジン類、これらの類似体、および方法
WO2008144253A1 (en) * 2007-05-14 2008-11-27 Irm Llc Protein kinase inhibitors and methods for using thereof
SI2299821T1 (sl) 2008-06-10 2016-03-31 Abbvie Inc. Triciklične spojine
JP2010143829A (ja) 2008-12-16 2010-07-01 Dainippon Sumitomo Pharma Co Ltd 新規なイミダゾキノリン誘導体
RU2011142182A (ru) 2009-03-19 2013-04-27 Медикал Рисерч Каунсил Текнолоджи Соединения
PL2506716T3 (pl) 2009-12-01 2017-10-31 Abbvie Inc Nowe związki tricykliczne
US8785639B2 (en) 2009-12-01 2014-07-22 Abbvie Inc. Substituted dihydropyrazolo[3,4-D]pyrrolo[2,3-B]pyridines and methods of use thereof
TW201204727A (en) 2010-03-10 2012-02-01 Kalypsys Inc Heterocyclic inhibitors of histamine receptors for the treatment of disease
WO2012143143A1 (en) 2011-04-21 2012-10-26 Origenis Gmbh Heterocyclic compounds as kinase inhibitors
US10000482B2 (en) 2012-10-19 2018-06-19 Origenis Gmbh Kinase inhibitors

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009155527A2 (en) * 2008-06-19 2009-12-23 Progenics Pharmaceuticals, Inc. Phosphatidylinositol 3 kinase inhibitors
WO2010030785A2 (en) * 2008-09-10 2010-03-18 Kalypsys Inc. Heterocyclic inhibitors of histamine receptors for the treatment of disease

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
CAS Registry Number 304872-03-5; STN Entry Date 29 November 2000; 3H-Pyrazolo[3,4-c][1,6]naphthyridine-1,4-diamine, N4-[2-(dimethylamino)ethyl]-6,7,8,9-tetrahydro-8-(phenylmethyl)- *
CAS Registry Number 304879-41-2; STN Entry Date 29 November 2000; Pyrano[4,3-b]pyrazolo[4,3-d]pyridin-1-amine, 3,6,7,9-tetrahydro-7,7-dimethyl-4-(phenylmethyl)- *
CAS Registry Number 327100-02-7; STN Entry Date 14 March 2001; 3H-Pyrazolo[3,4-c][1,6]naphthyridine-1,4-diamine, 6,7,8,9-tetrahydro-8-(phenylmethyl)-N4-propyl- *
CAS Registry Number 368839-23-0; STN Entry Date 11 November 2001; Pyrano[4,3-b]pyrazolo[4,3-d]pyridin-1-amine, 3,6,7,9-tetrahydro-7,7-dimethyl-4-(2-methylpropyl)- *
CAS Registry Number 382610-70-0; STN Entry Date 14 January 2002; Pyrano[4,3-b]pyrazolo[4,3-d]pyridin-1-amine, 3,6,7,9-tetrahydro-7,7-dimethyl-4-propyl- *
CAS Registry Number 383161-12-4; STN Entry Date 15 January 2002; Pyrazolo[4,3-d]thiopyrano[3,4-b]pyridin-1-amine, 4-butyl-3,6,8,9-tetrahydro-8,8-dimethyl- *

Also Published As

Publication number Publication date
KR20140009495A (ko) 2014-01-22
AP2013007252A0 (en) 2013-11-30
AU2012244549A1 (en) 2013-10-31
CN103717597B (zh) 2017-07-04
EP2699572A1 (en) 2014-02-26
ECSP13012984A (es) 2014-09-30
PE20140927A1 (es) 2014-08-24
JP6278406B2 (ja) 2018-02-14
TN2013000422A1 (en) 2015-03-30
US20120329785A1 (en) 2012-12-27
CR20130537A (es) 2014-03-13
TW201247666A (en) 2012-12-01
GT201300259A (es) 2016-07-07
KR101649610B1 (ko) 2016-08-19
BR112013026744B1 (pt) 2022-05-17
EP2699572B1 (en) 2016-08-10
EA034193B1 (ru) 2020-01-15
PH12013502184A1 (en) 2014-01-13
HK1192247A1 (zh) 2014-08-15
CL2013003052A1 (es) 2014-05-23
WO2012143143A1 (en) 2012-10-26
EA201301183A1 (ru) 2014-04-30
CU20130144A7 (es) 2014-02-28
IL228967B (en) 2018-06-28
JP2014511884A (ja) 2014-05-19
MX365784B (es) 2019-05-28
MX2013012295A (es) 2014-03-27
MA35123B1 (fr) 2014-05-02
CO6831983A2 (es) 2014-01-10
US9499535B2 (en) 2016-11-22
TWI557121B (zh) 2016-11-11
CA2831680C (en) 2020-04-21
BR112013026744A2 (enExample) 2017-01-03
CN103717597A (zh) 2014-04-09
SG194216A1 (en) 2013-11-29
CA2831680A1 (en) 2012-10-26
IL228967A0 (en) 2013-12-31

Similar Documents

Publication Publication Date Title
AU2012244549B2 (en) Heterocyclic compounds as kinase inhibitors
AU2012244550C1 (en) Pyrazolo [4, 3-d] pyrimidines useful as kinase inhibitors
MX2015004327A (es) Derivados de pirrolotriazinona como inhibidores de pi3k.
TWI816704B (zh) 苯并咪唑衍生物及其用途
TW202106669A (zh) 作為ｍｒｇｘ２抑制劑之３—胺基—４ｈ—苯并［ｅ］［１，２，４］噻二嗪１，１—二氧化物衍生物
JP6339564B2 (ja) 抗マラリア剤としてのピリミジノン誘導体
CA3011176A1 (en) 3-((hetero-)aryl)-8-amino-2-oxo-1,3-diaza-spiro-[4.5]-decane derivatives
HK1192247B (en) Heterocyclic compounds as kinase inhibitors
HK1192248B (en) Pyrazolo[4,3-d]pyrimidines useful as kinase inhibitors

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)